311 related articles for article (PubMed ID: 33575935)
1. Safety and effectiveness of everolimus in maintenance kidney transplant patients in the real-world setting: results from a 2-year post-marketing surveillance study in Japan.
Hayase N; Yamada M; Kaneko S; Watanabe Y
Clin Exp Nephrol; 2021 Jun; 25(6):660-673. PubMed ID: 33575935
[TBL] [Abstract][Full Text] [Related]
2. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials.
Lee SG; Jeng LB; Saliba F; Singh Soin A; Lee WC; De Simone P; Nevens F; Suh KS; Fischer L; Jin Joo D; Fung J; Joh JW; Kaido T; Grant D; Meier M; Rauer B; Sips C; Kaneko S; Levy G
Transplantation; 2021 Jul; 105(7):1564-1575. PubMed ID: 33741847
[TBL] [Abstract][Full Text] [Related]
4. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
Fischer L; Saliba F; Kaiser GM; De Carlis L; Metselaar HJ; De Simone P; Duvoux C; Nevens F; Fung JJ; Dong G; Rauer B; Junge G;
Transplantation; 2015 Jul; 99(7):1455-62. PubMed ID: 26151607
[TBL] [Abstract][Full Text] [Related]
5. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
[TBL] [Abstract][Full Text] [Related]
6. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients.
Nanmoku K; Kurosawa A; Kubo T; Shinzato T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2017 Oct; 49(8):1724-1728. PubMed ID: 28923615
[TBL] [Abstract][Full Text] [Related]
7. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
8. Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial.
Cillo U; Saracino L; Vitale A; Bertacco A; Salizzoni M; Lupo F; Colledan M; Corno V; Rossi G; Reggiani P; Baccarani U; Bresàdola V; De Carlis L; Mangoni I; Ramirez Morales R; Agnes S; Nure E
Liver Transpl; 2019 Feb; 25(2):242-251. PubMed ID: 30592371
[TBL] [Abstract][Full Text] [Related]
9. Safety and Effectiveness of Once-Daily, Prolonged-Release Tacrolimus in De Novo Kidney Transplant Recipients: 5-year, Multicenter Postmarketing Surveillance in Japan.
Wakasugi N; Uchida H; Uno S
Transplant Proc; 2018 Dec; 50(10):3296-3305. PubMed ID: 30577199
[TBL] [Abstract][Full Text] [Related]
10. Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years.
Saliba F; Duvoux C; Dharancy S; Dumortier J; Calmus Y; Gugenheim J; Kamar N; Salamé E; Neau-Cransac M; Vanlemmens C; Durand F; Pageaux G; Leroy V; Hardwigsen J; Gharbi H; Masson C; Tindel M; Conti F
Liver Transpl; 2019 Dec; 25(12):1822-1832. PubMed ID: 31631501
[TBL] [Abstract][Full Text] [Related]
11. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function.
Nojima M; Yamada Y; Higuchi Y; Shimatani K; Kanematsu A; Yamamoto S
Transplant Proc; 2017; 49(1):41-44. PubMed ID: 28104155
[TBL] [Abstract][Full Text] [Related]
14. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
Nogueras López F; Abellan Alfocea P; Ortega Suazo EJ; López Garrido MA; Becerra Massare A; Gila Medina AM; Redondo Cerezo E; Espinosa Aguilar MD
Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
[TBL] [Abstract][Full Text] [Related]
15. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients.
Manzia TM; Angelico R; Toti L; Grimaldi C; Sforza D; Vella I; Tariciotti L; Lenci I; Breshanaj G; Baiocchi L; Tisone G
Transplant Proc; 2018; 50(1):175-183. PubMed ID: 29407305
[TBL] [Abstract][Full Text] [Related]
16. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
Cruzado JM; Pascual J; Sánchez-Fructuoso A; Serón D; Díaz JM; Rengel M; Oppenheimer F; Hernández D; Paravisini A; Saval N; Morales JM;
Transpl Int; 2016 Dec; 29(12):1317-1328. PubMed ID: 27648523
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
Miura M; Higashiyama H; Fukasawa Y; Itoh Y; Tamaki T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
[TBL] [Abstract][Full Text] [Related]
18. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis.
Mocchegiani F; Montalti R; Nicolini D; Svegliati Baroni G; Benedetti A; Risaliti A; Vivarelli M
Ann Transplant; 2014 Oct; 19():545-50. PubMed ID: 25347718
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.
Felipe CR; Oliveira NI; Hannun PG; de Paula MI; Tedesco-Silva H; Medina-Pestana JO
Ther Drug Monit; 2016 Feb; 38(1):64-72. PubMed ID: 26274696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]